

Rare Disease Day 27 February 2015 Patients and Researchers, Partners for Life!

Agenda

7:30 a.m. Registration and Poster/Exhibit Booth Set-up

8:30 a.m. First Morning Session

- Opening Remarks John I. Gallin, M.D. – Director, Clinical Center, National Institutes of Health (NIH)
- How The Children's Inn Supports Rare Disease Research Jennie Lucca – Chief Executive Officer, The Children's Inn at NIH
- Congressional Remarks Congressman Leonard Lance – Representative (R – NJ 7th District)
- New Treatment for a Rare Metabolic Disorder
 William H. Theodore, M.D. Chief, Clinical Epilepsy Section, National Institute of Neurological Disorders and Stroke (NINDS), NIH
- Food and Drug Administration (FDA) Updates Gayatri Rao, M.D., J.D. – Director, Office of Orphan Product Development, FDA
- National Organization for Rare Disorders (NORD) Updates Diane Dorman – Vice President, Public Policy, NORD

10:00 a.m. Morning Break

10:15 a.m. Second Morning Session

Team and Community Building Discussion Panel

- Academic Team Model Maureen Hoatlin, Ph.D., M.B.A. – Associate Professor, Oregon Health & Science University
- Patient Advocacy Group Team Model
 Jill Wood Co-Founder and Chief Financial Officer, Jonah's Just Begun
- Patient Advocacy Group Community Building Model Matt Might, Ph.D. – President, NGLY1.org
- Foundation-Directed Team Model Barbara L. Handelin, Ph.D. – Chief Executive Officer, BioPontis Alliance

Genetic Alliance Updates

James O'Leary, M.B.A. – Chief Innovation Officer, Genetic Alliance

12:00 p.m. Lunch and Poster Session / Clinical Center Tours







1:30 p.m. First Afternoon Session

NIH Director Remarks

Francis S. Collins, M.D., Ph.D. – Director, NIH

Technology Hand-Off Discussion Panel

- Technology Transfer at the National Center for Advancing Translational Sciences (NCATS) Lili M. Portilla, M.P.A. – Director, Office of Strategic Alliances, NCATS
- Experiences of an Inventor: From Intramural to Biotech Robert Kotin, Ph.D. – Vice President of Production, Voyager Therapeutics, Inc.
- Technology Transfer: A Success Story Stephen Seiler – Founder, AesRx, LLC

Global Genes Updates

Barbara Lavery – Vice President of Strategic Alliances, Global Genes

Uplifting Athletes Updates

Scott Shirley – Executive Director, Uplifting Athletes

- 3:00 p.m. Afternoon break
- 3:15 p.m. Second afternoon session

NCATS Director Remarks

Christopher P. Austin, M.D. – Director, NCATS

Rare Diseases Clinical Research Network (RDCRN)

- RDCRN Update Rashmi Gopal-Srivastava, Ph.D. – Program Director, NCATS
- RDCRN Patient Advocate Charles A. Mohan, Jr. – Chair, Coalition of Patient Advocacy Groups
- RDCRN Program Officer
 Wendy R. Galpern, M.D., Ph.D. Program Director, Clinical Trials, NINDS
- **RDCRN Principal Investigator** Peter A. Merkel, M.D, M.P.H. – Chief, Division of Rheumatology, University of Pennsylvania
- 4:45 p.m. Wrap Up
- 5:00 p.m. Adjourn